Seongjun So, Mustafa Zafer Karagozlu, Yeonmi Lee, Eunju Kang
언어
영어(ENG)
URL
https://www.earticle.net/Article/A378885
※ 기관로그인 시 무료 이용이 가능합니다.
4,000원
원문정보
초록
영어
Somatic cell nuclear transfer derived embryonic stem cells (NT-ESCs) have significant advantages in various fields such as genetics, embryology, stem cell science, and regenerative medicine. However, the poor establishment of NT-ESCs hinders various research. Here, we applied fasudil, a Rho-associated kinase (ROCK) inhibitor, to develop somatic cell nuclear transfer (SCNT) embryos and establish NT-ESCs. In the study, MII oocytes were isolated from female B6D2F1 mice and performed SCNT with mouse embryonic fibroblasts (MEFs). The reconstructed NT-oocytes were activated artificially, and cultured to blastocysts in KSOM supplemented with 10 μM fasudil. Further, the blastocysts were seeded on inactivated MEFs in embryonic stem cell medium supplemented with 10 μM fasudil. A total of 26% of embryos formed into blastocysts in the fasudil treated group, while this ratio was 44% in the fasudil free control group. On the other hand, 30% of blastocysts were established NT-ESCs after exposure of fasudil, which was significantly higher than the control group (10%). The results suggest that fasudil reduced blastocyst development after SCNT due to inhibition of 2 cell cleavage while improved the establishment of NT-ESCs through the anti-apoptotic pathway.
목차
ABSTRACT INTRODUCTION MATERIALS AND METHODS Ethics and governance Treatment of fasudil Preparation of nuclear donor cells Collection of oocytes Somatic cell nuclear transfer (SCNT) Artificial activation of oocytes and embryo culture Establishment of NT-mESC lines Statistical analysis RESULTS Effects of fasudil on NT-embryo development Fasudil increases the establishment of NT-mESCs DISCUSSION CONCLUSION CONFLICTS OF INTEREST ACKNOWLEDGEMENTS AUTHOR CONTRIBUTIONS AUTHOR’S POSITION AND ORCID NO. REFERENCES
Seongjun So [ Department of Convergence Medicine & Stem Cell Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea ]
Mustafa Zafer Karagozlu [ Department of Convergence Medicine & Stem Cell Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea ]
Yeonmi Lee [ Department of Convergence Medicine & Stem Cell Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea ]
Eunju Kang [ Department of Convergence Medicine & Stem Cell Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea ]
Corresponding Author